



MEDIA RELEASE

Contact: Joseph Burkett
336-387-1006
joseph.burkett@novartis.com

or Julie Groce
336-387-1080
julie.groce@novartis.com

Novartis announces removal of Denagard® weight restriction

Greensboro, NC (June 16, 2008) – Pork producers can now use Denagard® (tiamulin) 10 Medicated Premix to combat costly enteric diseases in pigs weighing more than 250 pounds. The Food and Drug Administration recently accepted the removal of the weight limit.

“Denagard is effective in pigs and market hogs of all ages, and now with the weight restriction removed, producers can use the product to control disease in animals weighing more than 250 pounds,” says Steve Boren, head of the U.S. farm animal business for Novartis.

“Ileitis is a common disease concern in these animals,” explains Boren. “Denagard 10 is an excellent option to control ileitis because it requires a smaller dosage – only 35 g/ton – and less medication time – as little as 10 days – than other ileitis treatments.”

Denagard also can be used for swine dysentery. When broader coverage is needed, Denagard can be fed with chlortetracycline (CTC).

As always, be sure to follow label directions and required withdrawal times. For more information, contact Novartis at 1-800-843-3386 or visit www.livestock.novartis.com.

Caution: Do not feed undiluted. Do not use in feeds for animals other than swine. The effects of tiamulin on swine reproductive performance, pregnancy and lactation have not been determined.

Novartis Animal Health researches, develops and commercializes leading animal treatments that meet the needs of pet owners, farmers and veterinarians. Headquartered in Basel, Switzerland, Novartis Animal Health conducts business in 40 countries and employs about 2,700 people worldwide. For more information, please consult www.livestock.novartis.com.

About Novartis

Novartis AG provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on growth areas in healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, and consumer health products. Novartis is the only company with leading positions in these areas.

In 2007, the Group's continuing operations (excluding divestments in 2007) achieved net sales of USD 38.1 billion and net income of USD 6.5 billion. Approximately USD 6.4 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 98,200 full-time associates and operate in over 140 countries around the world. For more information, please visit <http://www.novartis.com>.

#